Currently, there are 160.21M common shares owned by the public and among those 156.66M shares have been available to trade.
The company’s stock has a 5-day price change of -48.98% and -82.81% over the past three months. IRWD shares are trading -85.37% year to date (YTD), with the 12-month market performance down to -91.91% lower. It has a 12-month low price of $0.90 and touched a high of $8.45 over the same period. IRWD has an average intraday trading volume of 3.33 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -50.60%, -58.73%, and -83.19% respectively.
Institutional ownership of Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) shares accounts for 101.76% of the company’s 160.21M shares outstanding.
It has a market capitalization of $104.84M and a beta (3y monthly) value of 0.45. The stock’s trailing 12-month PE ratio is 59.99, while the earnings-per-share (ttm) stands at $0.01. The company has a PEG of 0.43 and a Quick Ratio of 4.69. Price movements for the stock have been influenced by the stock’s volatility, which stands at 17.25% over the week and 10.36% over the month.
Earnings per share for the fiscal year are expected to increase by 769.75%, and 308.51% over the next financial year. EPS should grow at an annualized rate of 141.01% over the next five years, compared to -47.49% over the past 5-year period.
Leerink Partners coverage for the Ironwood Pharmaceuticals Inc (IRWD) stock in a research note released on September 09, 2024 offered a Market Perform rating with a price target of $5. CapitalOne was of a view on August 08, 2024 that the stock is Equal Weight, while Craig Hallum gave the stock Buy rating on January 17, 2024, issuing a price target of $21. Wells Fargo on their part issued Overweight rating on December 14, 2023.
